A PET study in healthy subjects of brain exposure of (11)C-labelled osimertinib – A drug intended for treatment of brain metastases in non-small cell lung cancer

Osimertinib is a tyrosine kinase inhibitor (TKI) of the mutated epidermal growth factor receptor (EGFRm) with observed efficacy in patients with brain metastases. Brain exposure and drug distribution in tumor regions are important criteria for evaluation and confirmation of CNS efficacy. The aim of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Cereb Blood Flow Metab
Main Authors: Varrone, Andrea, Varnäs, Katarina, Jucaite, Aurelija, Cselényi, Zsolt, Johnström, Peter, Schou, Magnus, Vazquez-Romero, Ana, Moein, Mohammad M, Halldin, Christer, Brown, Andrew P, Vishwanathan, Karthick, Farde, Lars
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2019
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7168784/
https://ncbi.nlm.nih.gov/pubmed/31006308
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0271678X19843776
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados